Predict your next investment

Venture Capital

See what CB Insights has to offer

Investments

10

Portfolio Exits

2

Funds

1

About Acorn Bioventures

Acorn Bioventures invests in private and small-capitalization biotech, specialty pharma and medical device companies.

Acorn Bioventures Headquarter Location

420 Lexington Avenue Suite 2626

New York, New York, 10170,

United States

202-299-4770

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Acorn Bioventures News

Q32 Bio Raises $60M in Series B Financing

Nov 4, 2020

Q32 Bio , a Cambridge, Mass.-based biotechnology company developing biologic therapeutics to restore healthy immune regulation, closed a $60m Series B financing. The round was co-led by OrbiMed Advisors and Acorn Bioventures with participation from Osage University Partners, Atlas Venture, Abingworth, Sanofi Ventures, University of Colorado and Children’s Hospital Colorado Center for Innovation. In conjunction with the financing, Isaac Manke (Acorn Bioventures) and Diyong Xu (OrbiMed Advisors) will join the Q32 Bio Board of Directors. The company intends to use the funds to advance: ADX-914 through demonstration of proof-of-mechanism, its tissue-targeted complement regulation platform, and both its platform and pipeline. Led by Michael Broxson, CEO, Q32 Bio is a clinical stage biotechnology company developing therapies targeting regulators of the innate and adaptive immune systems to re-balance immunity in severe autoimmune and inflammatory diseases. Its lead programs, focused on the IL-7R pathway and complement system, address immune dysregulation to help patients take back control of their lives. The first-in-human trial for the company’s most advanced program, ADX-914, a fully human anti-IL-7R antibody, is designed to evaluate safety and tolerability and demonstrate proof-of-mechanism. IL-7 has been genetically and biologically validated to drive several T cell-mediated pathological processes in numerous autoimmune diseases. Q32 Bio’s lead program for innate immunity, ADX-097, is a fusion protein generated by its complement platform and is expected to enter Phase 1 in the fourth quarter of 2021. FinSMEs 04/11/2020

Acorn Bioventures Investments

10 Investments

Acorn Bioventures has made 10 investments. Their latest investment was in Eliem Therapeutics as part of their Series B on May 5, 2021.

CBI Logo

Acorn Bioventures Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

5/24/2021

Series B

Eliem Therapeutics

$60M

Yes

4

3/4/2021

Series B

OnKure

$55M

Yes

4

2/8/2021

PIPE

Gemini Therapeutics

$95M

Yes

1

12/22/2020

PIPE - III

Subscribe to see more

$99M

Subscribe to see more

10

12/16/2020

Series B

Subscribe to see more

$99M

Subscribe to see more

10

Date

5/24/2021

3/4/2021

2/8/2021

12/22/2020

12/16/2020

Round

Series B

Series B

PIPE

PIPE - III

Series B

Company

Eliem Therapeutics

OnKure

Gemini Therapeutics

Subscribe to see more

Subscribe to see more

Amount

$60M

$55M

$95M

$99M

$99M

New?

Yes

Yes

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

4

4

1

10

10

Acorn Bioventures Portfolio Exits

2 Portfolio Exits

Acorn Bioventures has 2 portfolio exits. Their latest portfolio exit was Eliem Therapeutics on August 10, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

8/10/2021

IPO

$991

1

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

Date

8/10/2021

00/00/0000

Exit

IPO

Subscribe to see more

Companies

Subscribe to see more

Valuation

$991

Acquirer

Subscribe to see more

Sources

1

10

Acorn Bioventures Fund History

1 Fund History

Acorn Bioventures has 1 fund, including Acorn Bioventures.

Closing Date

Fund

Fund Type

Status

Amount

Sources

3/25/2020

Acorn Bioventures

Early-Stage Venture Capital

$199.5M

1

Closing Date

3/25/2020

Fund

Acorn Bioventures

Fund Type

Early-Stage Venture Capital

Status

Amount

$199.5M

Sources

1

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.